Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pathogens

- PMLiVE

JCVI recommends spring COVID-19 booster for those at highest risk

Eligible individuals will be offered the booster around six months after their previous dose

- PMLiVE

WHO countries begin negotiations on global pandemic preparedness agreement

The discussions will continue over the next year until a final draft is made in 2024

Streamlining Healthcare Delivery Through Digital Care Journeys

Dr. Joshua Liu, Co-founder & CEO of SeamlessMD, explores how technology and “Digital Care Journeys” can help hospitals reduce the surgical backlog for high-volume procedures like hip and knee replacements,...

Impetus Digital

- PMLiVE

Pfizer/BioNTech submit FDA application for Omicron-adapted booster for young children

The vaccine is already authorised as the third of a three-dose primary series in this age group

- PMLiVE

FDA authorises first at-home COVID-19 and flu test for emergency use

The single-use test uses nasal swab samples and provides results in about 30 minutes

- PMLiVE

Gilead reports positive real-world evidence for COVID-19 treatment Veklury

A study of more than 500,000 hospitalised patients showed a reduction in mortality risk

- PMLiVE

Merck and Ridgeback’s COVID-19 pill fails to prevent infection within households

Lagevrio is already approved to treat certain patients with COVID-19 in several markets

Applying Vibrotactile Stimulation to Improve Parkinson’s

Lucy Jung, CEO & Founder of Charco Neurotech, shares how meeting members of the Parkinson's community catalyzed the founding of Charco and how #innovative medical devices and software can improve...

Impetus Digital

- PMLiVE

AstraZeneca’s Evusheld not recommended by NICE for COVID-19 prevention

The agency said there is not enough evidence of the drug’s effectiveness against current variants

- PMLiVE

GSK and Vir Biotech amend COVID-19 research partnership

Vir will now advance new antibodies and vaccines for COVID-19 alone or with other partners

- PMLiVE

Eiger BioPharmaceuticals reports positive phase 3 results for COVID-19 treatment

Peginterferon lambda showed a 51% reduction in hospitalisations or emergency room visits

- PMLiVE

NHS urges people yet to receive their COVID-19 booster to come forward

Sunday 12 February is the last day people under 50 years of age who are not considered at risk can receive a booster

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links